Finding the right treatment for moderate plaque psoriasis can be tough. Your skin health is key to your overall well-being and confidence.
Recent studies show big differences in modern treatments. When comparing skyrizi vs otezla, people want the best for clear skin. IL-23 inhibitors often lead to better results than PDE-4 inhibitors.
At Liv Hospital, we focus on patient-centered care based on the latest research. Whether you’re looking into otezla vs skyrizi or need a custom plan, our team is here to help. We aim to offer both medical expertise and caring support for your healing.
Key Takeaways
- Choosing the right systemic therapy is essential for long-term skin health.
- Clinical studies indicate that IL-23 inhibitors often outperform traditional PDE-4 options.
- Individual patient needs should always guide the selection of medical treatments.
- Liv Hospital combines advanced research with a compassionate approach to care.
- Consulting with specialists helps clarify which medication aligns with your health goals.
Understanding the Burden of Moderate Plaque Psoriasis
Moderate plaque psoriasis affects more than just your skin. It changes how you dress and what social events you can join. We aim to help you take back control of your health and happiness.
The Global Impact of Psoriasis
Psoriasis is a common health issue, affecting about 2-3% of people worldwide. It’s not just about skin problems or visible patches.
Many people feel anxious and isolated because of psoriasis. They may stop going out and feel less happy. We know that treating psoriasis means tackling both the physical and emotional challenges it brings.
Defining Systemic Therapy Eligibility
Deciding when to move from creams to stronger treatments is a big step. For mild cases, creams might be enough. But moderate plaque psoriasis often needs more powerful treatments to really help.
We look at several things to see if systemic treatment is right for you. We consider how much of your body is affected, if creams haven’t worked, and how psoriasis affects your daily life.
| Treatment Stage | Primary Focus | Typical Intervention |
| Initial Care | Surface symptom relief | Topical creams and ointments |
| Advanced Care | Systemic inflammation control | Biologics or oral medications |
| Long-term Goal | Sustained skin clearance | Maintenance therapy and monitoring |
Our team is here to help you make these important decisions. We believe that informed patients are empowered patients. We want to make sure you understand every part of your treatment.
Clinical Comparison: Skyrizi vs Otezla
When we compare the ways different treatments work, it helps patients choose better for their skin. Looking at skyrizi vs otezla shows how each affects the body to fight inflammation.
Mechanism of Action: IL-23 Inhibitors vs PDE-4 Inhibitors
Skyrizi blocks the IL-23 protein. This is a major cause of inflammation in plaque psoriasis.
Otezla, on the other hand, is a PDE-4 inhibitor. It works inside cells to control inflammation. Knowing how each works is key when choosing between o, tezla vs skyrizi.
Analyzing the IMMpulse Study Results
The IMMpulse study is important for adults with plaque psoriasis. It compared these two treatments over 16 weeks.
By week 16, risankizumab showed better results. 55.9% of patients reached PASI 90, and 75.4% had a sPGA score of 0 or 1.
For apremilast, the numbers were lower. Only 5.1% reached PASI 90, and 18.4% had a sPGA score of 0 or 1. Also, risankizumab patients see visible skin improvement in just four weeks.
Switching Strategies and Long-Term Outcomes
Your skin health journey is unique, and sometimes you need to change your treatment. Finding the right medication is a journey, not a single choice. If your current treatment doesn’t work, there are other options to help you achieve your goals.
Transitioning from Otezla to Skyrizi
Many start with oral medications but may hit a plateau. When looking at skyrizi vs otezla, doctors might switch you if you’re not seeing results. This change can be a game-changer for many.
Switching from o, tezla vs skyrizi is a common move for better results. Moving to a targeted biologic can greatly reduce inflammation. It’s not a failure, but a step towards healthier skin.
Efficacy Data for Non-Responders
Studies show great results when patients switch to risankizumab at week 16. By week 52, the results are very promising.
Most patients see big improvements. 72.3% reach PASI 90, and 50.6% get complete clearance, PASI 100. These numbers show a clear path forward for those who’ve been disappointed before.
| Outcome Metric | Percentage Achieved | Clinical Significance |
| PASI 90 | 72.3% | High level of clearance |
| PASI 100 | 50.6% | Complete skin clearance |
| Observation Period | 52 Weeks | Long-term success |
Conclusion
Choosing the right treatment for moderate plaque psoriasis is key. You need to understand your health goals well. Skyrizi and Otezla offer different ways to manage symptoms.
The IMMpulse study shows Skyrizi is a strong option for quick and lasting skin improvement. It’s great for those not happy with their current treatment.
We suggest talking to your dermatologist about these findings. They can check if switching to Skyrizi is right for you.
Our team is here to help you on your health journey. We offer the support and resources you need to manage moderate plaque psoriasis confidently.
FAQ
When comparing skyrizi vs otezla, which treatment is more effective for achieving clear skin?
We look at clinical data, like the Phase 4 IMMpulse study. It shows Skyrizi (risankizumab) works better for clear skin by week 16. Patients on Skyrizi see improvements in their psoriasis in just four weeks.
What are the main differences between otezla vs skyrizi in terms of how they work?
Skyrizi blocks IL-23 cytokine to fight inflammation. Otezla, on the other hand, is a PDE-4 inhibitor that works inside cells. Knowing how they work helps us choose the best treatment for each patient.
Can I switch to Skyrizi if Otezla is not working for my plaque psoriasis?
Yes, switching treatments is common. Studies show switching to Skyrizi at week 16 can lead to great results. By week 52, 72.3% of patients reached PASI 90, and 50.6% got total skin clearance.
How do we determine systemic therapy eligibility for these advanced medications?
We consider systemic therapy when topical treatments don’t work well. Psoriasis affects 2-3% of people worldwide, impacting their lives. We move to Skyrizi or Otezla for better care.
What results should I expect from the IMMpulse study results regarding long-term clearance?
The IMMpulse study gives hope and realistic expectations. Skyrizi offers sustained results. Patients switching treatments have a high chance of reaching PASI 90 or 100 after a year, showing a clear path forward.
References
National Center for Biotechnology Information.https://pubmed.ncbi.nlm.nih.gov/37488811/
Departments
Related Videos
Our Doctors
News
